| Prev Close | 203.56 |
| Day Low/High | 200.81 / 204.12 |
| 52 Wk Low/High | 166.30 / 211.90 |
| Avg Volume | 2.94M |
Amgen Inc. (AMGN)
202.72
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 599.70M |
| Market Cap | 122.08B |
| EPS | 12.70 |
| P/E Ratio | 16.10 |
| Div & Yield | 5.80 (2.77%) |
Latest News
Jim Cramer: How to Survive This Violent Rotation
Emotions and panic must be checked at the door, if you are going to be a successful investor, especially right now.
Could Small Drug Trial Hold Big Potential for Amgen?
The results of a lung-cancer drug got me to go long on the stock, but the larger picture is complicated.
Amgen's Lower Open Tests Support but the Bigger Picture Is More Important
Let's check out the charts to get a sense of where prices could be headed.
A Sagging Drugmaker and Lagging Pet Health Name Both Worth Looks
Alexion Pharmaceuticals and Elanco Animal Health have seen their shares go to the dogs of late, but still offer reasons for portfolio consideration.
Real Money Post-Industrial Average Holds Own in Turbulent August
Gains in Amgen, CVS, and others helped offset declines in other stocks, as the RMPIA rose over the last two months to 0.6%, handily beating all the major domestic stock market averages.
Otezla Price Under Microscope -- but Look Closely and It Checks Out
Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.
M&A Appetite in Pharma Has Proved Potent: Chart of the Day
With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.
Amgen Charts Indicate Shares Want to Work Their Way Higher Longer Term
Amgen's deal to buy Otezla from Celgene should not deter the drugmaker's stock from gaining ground over the long haul.
Amgen Adds Celgene's Otezla to Bolster Pipeline at Pricey Valuation
Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.
A Pair of Rare Disease Biotech Concerns Worth a Good Look
Alexion Pharmaceuticals is a solid company that is the subject of acquisition rumors and Amicus Therapeutics has a key drug off to a strong start.
Fear Not the Curve, Sizing Up Earnings and Ways to Play Amgen: Market Recon
Understanding yourself and the investing environment you are in are keys to avoiding panic brought on by fear.
Real Money Post-Industrial Average Leads Major Indexes So Far for Year
In July, the RMPIA climbed 0.6%, bringing its year-to-date return to just over 21%.
Trading Apple and Netflix, Beyond Meat Earnings: Market Recon
Overall, expect trading volume, with notable exception of action in specific names reporting earnings, to remain on the light side right through later Wednesday afternoon.
Real Money Post Industrial Average Enjoyed a Stellar First Half of 2019
There are a number of RMPIA companies that will be beneficiaries of Back to School and holiday spending.
3 Autopilot Funds for a High-Yield Portfolio
This portfolio is built to hold up in any market, throw off a steady 8% dividend and pay monthly dividends, to boot.
AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal
The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.
Amgen Charts Indicate Bounce Possible Within a Longer-Term Downtrend
In the short run the stock of this biotech giant could bounce as momentum has slowed, but the bigger picture is for further weakness.
Teva Pharmaceuticals CEO: Stock on Track for 2020 Turnaround
But is a Teva turnaround still coming after the stock's 70% loss in the past five years?
Real Money Post-Industrial Average Leaves Major Indices in the Dust
RMPIA outperformed once gain during April.
Stalking an Entry in Pioneer Natural Resources Into Earnings
Plus a possible setup in Amgen as earnings approach.
Are These Stocks the Best of the Best?
Screening Goldman Sachs' list of the top 20 stocks to see which ones are the best technical opportunities.
Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot
In this day and age, companies must be 'disruptors' or get left in the dust.
The Real Money Post Industrial Average Continues to Soar
The RMPIA rose 10.5% during the first half of the current quarter.
Real Money Post-Industrial Average Shines in January, Outperforming S&P 500
RMPIA soared 9.9% for the month, led by 11 double-digit gainers.
